Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway

Background and Aims Lenvatinib is a first‐line drug commonly used in the treatment of advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is very limited due to drug resistance. Therefore, there is a great need to explore its combination with other agents to achieve better therap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2023-07, Vol.43 (7), p.1577-1592
Hauptverfasser:	Cheng, Yizhe, Zhan, Ping, Lu, Jing, Lu, Yuyan, Luo, Changhong, Cen, Xuesong, Wang, Fuqiang, Xie, Chengrong, Yin, Zhenyu
Format:	Artikel
Sprache:	eng
Schlagworte:	AKT AKT protein Animal models Anticancer properties Cancer Cholecystokinin combination Drug resistance Flow cytometry FOXO3 FOXO3 protein Hepatocellular carcinoma In vivo methods and tests Lenvatinib Liver cancer Metformin Molecular modelling Phosphorylation Signal transduction Signaling Translocation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!